Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.07.29.740903

Equi-depth pooling for standardized and cost-effective Adaptive Immune Receptor Repertoire sequencing (AIRRseq)

Abstract

Bulk B- and T-cell adaptive immune receptor (BCR/TCR) repertoire sequencing (AIRRseq) enables comprehensive analysis of adaptive immune diversity, but achieving balanced sequencing depth across heterogeneous clinical samples remains a major cost driver. Standard equimolar pooling prior to sequencing disproportionately allocates reads, leading to undersequencing of libraries with high sequence abundance and oversampling of those with few sequences. Here, a quantitative pooling strategy is described in which libraries are pooled based on estimated target-specific unique molecular identifier (UMI) counts rather than library molarity, ensuring a uniform number of supporting reads per target sequence UMI across samples. Libraries were prepared from human RNA using the NEBNext Immune Sequencing (IS) kit and quantified by qPCR during the second amplification (PCR2) step. Deeply sequenced samples from a dengue 1 human infection model (DHIM1) clinical study were used to model the log-linear relationship between PCR2 cycle threshold (Ct) values and detected sequence counts. This model was then applied to a second, independent batch of samples from a dengue 3 human infection model (DHIM3) clinical study to predict UMI abundance and guide equi-depth pooling prior to sequencing. Sequencing of these equi-depth pools demonstrated a near-uniform reads-per-sequence ratio across samples, confirming that this approach achieves balanced depth without oversampling and at reduced cost. Simulations across a range of between-sample UMI-count distributions reflecting real-world sample pools showed that equi-depth pooling is expected to reduce the total number of required sequencing reads by approximately 70% compared with equimolar pooling, with savings increasing as the spread of library sizes grows. Beyond cost efficiency, equi-depth pooling eliminates the complexity-dependent sampling bias inherent to equimolar pooling, ensuring uniform sequencing depth and comparable UMI recovery across small and large libraries. For new workflows or sample types, implementation requires either an existing calibration dataset or a pilot sequencing experiment to establish the relationship between PCR2 Ct values and relative UMI abundance. The equi-depth method thus provides a robust, scalable, and cost-efficient strategy for bulk AIRRseq studies where library sizes vary widely.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Verdonckt, T.-W., Sahulcik, M., Struyfs, C., Vermeersch, A.-S., Bartholomeeusen, K., Van Nieuwerburgh, F., Lagatie, O., Arien, K. K.. 2026-08-01. Equi-depth pooling for standardized and cost-effective Adaptive Immune Receptor Repertoire sequencing (AIRRseq). https://doi.org/10.64898/2026.07.29.740903

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗